eXp World (EXPI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Executive summary
Annual Meeting scheduled for May 8, 2026, with key proposals to be voted on, including redomestication from Delaware to Texas.
Board unanimously recommends moving legal domicile to Texas after over a year of consideration.
Texas is the top state by transaction sides and second by agent count and volume for the company.
Forward-looking statements highlight potential benefits, risks, and uncertainties related to the redomestication.
Voting matters and shareholder proposals
Main proposal is to approve the redomestication of the company from Delaware to Texas.
Shareholders are urged to vote before May 8, 2026, with proxy solicitation support provided.
Board of directors and corporate governance
Texas law would allow directors and officers to consider interests of key constituencies, including agents, in decision-making.
Governance framework is expected to better align with business realities post-redomestication.
Latest events from eXp World
- Shareholders will vote on redomestication to Texas, with key risks and benefits highlighted.EXPI
Proxy filing23 Apr 2026 - Shareholders will vote on redomestication to Texas, with new litigation thresholds and outlined risks.EXPI
Proxy filing23 Apr 2026 - Shareholders are voting on a Texas redomestication, with enhanced governance and voting safeguards.EXPI
Proxy filing23 Apr 2026 - Stockholders will vote on redomestication to Texas, aiming for financial and governance benefits.EXPI
Proxy filing22 Apr 2026 - Proxy solicitor engaged for 2026 Annual Meeting to support redomestication vote.EXPI
Proxy filing20 Apr 2026 - Shareholders to vote on Texas redomestication, governance, and compensation changes.EXPI
Proxy Filing9 Mar 2026 - Board recommends approval of director elections, auditor, executive pay, and Texas redomestication.EXPI
Proxy Filing25 Feb 2026 - 2025 revenue rose 4% to $4.8B, with 67% international growth and strong agent productivity.EXPI
Q4 202524 Feb 2026 - Q2 2024 revenue up 5% to $1.3B, adjusted EBITDA up 22%, and $56M returned to shareholders.EXPI
Q2 20242 Feb 2026